Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17203211 | 0.89 | VCAM1 (0.46) | VCAM1GAATSHRKMT2AALB | |
| SCHEMBL4081074 | 0.86 | KMT2A (0.45) | GAAHPGDKMT2AMEN1ALDH1A1 | |
| Alcohol SCHEMBL10867294 | 0.81 | VCAM1 (0.46) | VCAM1TSHRKMT2AMEN1ALB | |
| SCHEMBL8651557 | 0.81 | KMT2A (0.44) | VCAM1TSHRKMT2AMEN1ALB | |
| Orcinol SCHEMBL2849303 | 0.81 | HCAR1 (0.52) | GAATSHRKMT2AMEN1HCAR1 | |
| SCHEMBL28471205 | 0.81 | VCAM1 (0.46) | VCAM1GAATSHRKMT2AMEN1 | |
| SCHEMBL2875378 | 0.80 | CA12 (0.56) | VCAM1HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL9774288 | 0.78 | ACHE (0.45) | GAAHPGDKMT2AMEN1HCAR1 | |
| SCHEMBL8654408 | 0.77 | KMT2A (0.48) | VCAM1KMT2AMEN1ALBALDH1A1 | |
| SCHEMBL11579542 | 0.77 | L3MBTL1 (0.56) | GAATSHRKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150119-B1 | DIHYDROXYBENZOATE POLYMERS AND USES THEREOF | TYRX INC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9491966-B2 | Dihydroxybenzoate polymers and uses thereof | TYRX, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20100129417-A1 | Dihydroxybenzoate Polymers and Uses Thereof | MEDTRONIC, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2150119-A1 | DIHYDROXYBENZOATE POLYMERS AND USES THEREOF | TYRX PHARMA INC. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008137807-A1 | DIHYDROXYBENZOATE POLYMERS AND USES THEREOF | TYRX PHARMA, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129417-A1 | Dihydroxybenzoate Polymers and Uses Thereof | DDT, QDPR, HPD | VCAM1 1243/4885GAA 891/4885TSHR 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.